Are compounded bioidentical hormones safe?
Direct Answer
Compounded bioidentical hormones are considered less safe than FDA-approved options because they lack federal oversight for purity, potency, and safety. While they use "natural" hormones, the unregulated nature of compounding pharmacies means doses can vary significantly, increasing risks of under-treatment or uterine over-stimulation.
Detailed Explanation
The debate over compounded bioidentical hormone therapy (cBHT) is one of the most polarized in menopause medicine. While cBHT is often marketed as a "natural," "safer," and "customized" alternative to conventional hormone therapy, major medical organizations—including the North American Menopause Society (NAMS), the FDA, and the National Academies of Sciences, Engineering, and Medicine (NASEM)—have issued strong statements cautioning against their widespread use. To make an informed choice, it is vital to separate marketing claims from clinical evidence.
The primary safety concern with compounded hormones is the lack of regulatory oversight. When a drug is FDA-approved, it must undergo years of clinical trials to prove its efficacy and safety. Furthermore, every batch manufactured in a regulated laboratory must meet strict standards for purity and potency. Compounding pharmacies are not subject to these same federal standards. Research has shown that the amount of actual hormone in a compounded preparation can vary significantly from what is written on the label—sometimes containing far too little, and other times far too much.
This variability carries real medical risks. If a compounded estrogen cream contains too little hormone, the woman's symptoms (like hot flashes or bone loss) will not be adequately treated. More dangerously, if a compounded "custom" progesterone cream contains too little hormone or is not absorbed properly, it will not protect the uterine lining from the stimulating effects of estrogen, which can lead to endometrial thickening and an increased risk of uterine cancer.
Marketing for cBHT often relies on the idea of "customization" based on hormone testing (using saliva, blood, or urine). However, clinical consensus is that one-time hormone levels are a poor metric for dosing. Especially in perimenopause, hormone levels can fluctuate wildly from hour to hour. Dosing based on a single "snapshot" is not scientifically supported and has not been shown to improve outcomes compared to adjusting regulated doses based on a woman's clinical symptoms and health history.
Another safety issue is the lack of standardized "Package Inserts." Every FDA-approved medication comes with a comprehensive document detailing all known side effects and risks based on clinical trials. Compounded hormones do not have these inserts, which can lead women to believe they are "risk-free" when, in fact, they carry the same biological risks as any other hormone therapy.
Proponents of compounding often point to the fact that they can provide hormones in unique delivery systems—such as pellets or sublingual drops—that are not available via standard prescription. While these are convenient, they are often associated with extremely high, "supra-physiological" levels of hormones (especially testosterone) that can lead to side effects like acne, hair loss, and voice changes.
For the vast majority of women, there is a safer path: FDA-approved bioidentical hormones. Many regulated patches, gels, and tablets use the exact same bioidentical hormones (17-beta estradiol and micronized progesterone) as compounding pharmacies but with the added protection of FDA oversight and proven safety profiles. NAMS and other societies recommend that compounded hormones be reserved ONLY for women who have a documented allergy to a specific ingredient in a mass-produced, regulated medication.
In summary, while the word "bioidentical" sounds reassuring, the "compounded" method of delivery introduces unnecessary risks. By choosing FDA-regulated formulations, women can benefit from the safety of Body-Identical hormones without the uncertainty of an unregulated manufacturing process.
Evidence Context
The risks of cBHT are established through expert consensus reports from NASEM and NAMS. We distinguish between "regulated bioidenticals" and "compounded bioidenticals." We prioritize the NASEM 2020 report which found insufficient evidence to support the safety or efficacy of compounded hormones for general menopause management.